| Schedule of Computation of Basic and Diluted Net Loss Per Share |
The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2026, and 2025 (in thousands, except number of shares): | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Numerator: | | | | | | | | | Net loss | $ | (10,599) | | | $ | (21,126) | | | $ | (16,133) | | | $ | (40,784) | | | Net loss attributable to noncontrolling interest | 19 | | | 2 | | | 22 | | | 12 | | | Net loss attributable to Barinthus Biotherapeutics plc shareholders | $ | (10,580) | | | $ | (21,124) | | | $ | (16,111) | | | $ | (40,772) | | | Denominator: | | | | | | | | | Weighted-average ordinary shares outstanding, basic | 40,848,893 | | 40,343,521 | | 40,848,893 | | 40,304,584 | | | | | | | | | | Weighted-average ordinary shares outstanding, diluted | 40,848,893 | | 40,343,521 | | 40,848,893 | | 40,304,584 | | Net loss per share attributable to ordinary shareholders, basic | $ | (0.26) | | | $ | (0.52) | | | $ | (0.39) | | | $ | (1.01) | | | Net loss per share attributable to ordinary shareholders, diluted | $ | (0.26) | | | $ | (0.52) | | | $ | (0.39) | | | $ | (1.01) | |
|